Upcoming Events
Log In
Pricing
Free Trial

Diagnostic CEM and Radiomics

HIDE
PrevNext

0:00

Another area to, um, for the future, is there's a—

0:05

we're gonna look at how contrast mammo specifically

0:09

applies to palpable lumps, pathologic nipple discharge,

0:12

high-risk screening, evaluation, and screening

0:13

recalls. More studies to see, to see

0:17

how it compares to our standard of care.

0:20

There's a great trial called, um,

0:23

it's called the RACER Trial, Rapid Access to

0:25

Contrast-Enhanced Spectral Mammography in

0:27

women recalled from breast cancer screening.

0:29

This trial, um, is doing— is randomizing patients

0:33

to standard of care, which is mammography,

0:37

ultrasound versus CEM, and they're gonna look

0:39

at what the different performance is in terms of

0:42

cancer detection, follow-ups, biopsies, et cetera.

0:46

Missed cancers.

0:47

So that is gonna be really one of— this is gonna—

0:50

the results of this trial are gonna be really great

0:52

to help us figure out is contrast mammo better?

0:55

Maybe it has a slightly better or better cancer

0:57

detection rate, but maybe, um, there are other

0:59

challenges that we need to be mindful of.

1:03

Lastly, for future directions,

1:04

we're gonna talk about radiomics.

1:07

Uh, radiomics are really looking at differentiating

1:11

cancer subtypes, trying to figure out can we use

1:14

contrast mammo and the contrast that we see on these

1:17

images to differentiate benign from malignant disease,

1:20

and lastly, to evaluate axillary metastases.

Report

Faculty

Jordana Phillips, MD

Division Chief of Breast Imaging, Boston Medical Center

Boston Medical Center

Tags

Oncologic Imaging

Neoplastic

Mammography

Diagnosis & Staging

Breast

© 2025 Medality. All Rights Reserved.

Privacy ChoicesImage: Privacy ChoicesContact UsTerms of UsePrivacy Policy